Advertisement

Annals of Surgical Oncology

, Volume 25, Issue 6, pp 1633–1639 | Cite as

Value of Preoperative PET-CT in the Prediction of Pathological Stage of Gastric Cancer

  • Michihiro Kudou
  • Toshiyuki Kosuga
  • Takeshi Kubota
  • Kazuma Okamoto
  • Shuhei Komatsu
  • Katsutoshi Shoda
  • Hirotaka Konishi
  • Atsushi Shiozaki
  • Hitoshi Fujiwara
  • Tomohiro Arita
  • Ryo Morimura
  • Yasutoshi Murayama
  • Yoshiaki Kuriu
  • Hisashi Ikoma
  • Masayoshi Nakanishi
  • Eigo Otsuji
Gastrointestinal Oncology

Abstract

Background

Preoperative precise staging is essential for the treatment of gastric cancer (GC); however, the diagnostic accuracy of conventional modalities needs to be increased. The present study investigated the clinical value of positron emission tomography-computed tomography (PET-CT) for the staging of GC.

Methods

This was a retrospective study of 117 patients with a clinical diagnosis of advanced GC who underwent PET-CT followed by gastrectomy. The incidence of FDG uptake in the primary tumor or lymph nodes and its relationship with clinicopathological factors, particularly pathological stage (pStage) III/IV, were examined.

Results

FDG uptake in the primary tumor was noted in 83 patients (70.9%). FDG uptake in the lymph nodes was detected in 21 patients (17.9%), and its sensitivity and specificity for lymph node metastasis were 22.7 and 90.5%, respectively. Multiple logistic regression analyses showed that FDG uptake in the primary tumor (odds ratio (OR) 2.764; 95% confidence interval (CI) 1.104–7.459, p = 0.029) and that in the lymph nodes (OR 4.660; 95% CI 1.675–13.84, p = 0.003) were factors independently associated with pStage III/IV. FDG uptake in the primary tumor detected pStage III/IV with higher sensitivity (80.4%) and that in lymph nodes found pStage III/IV with higher specificity (88.7%) than those of upper endoscopy plus CT (60.9 and 67.6%, respectively).

Conclusions

PET-CT appears to be a useful complementary modality in the assessment of pStage III/IV because of the high sensitivity of FDG uptake in the primary tumor and the high specificity of FDG uptake in the lymph nodes.

Notes

Disclosure

The authors have no conflicts of interest.

References

  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMedGoogle Scholar
  2. 2.
    Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–93.CrossRefPubMedGoogle Scholar
  3. 3.
    Bang Y-J, Kim Y-W, Yang H-K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21.CrossRefPubMedGoogle Scholar
  4. 4.
    Kosuga T, Ichikawa D, Otsuji E. Pathologic tumor response to neoadjuvant chemotherapy in gastroesophageal cancer: what does it mean? Transl Gastroenterol Hepatol. 2016;1:75.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28(35):5210–8.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Boige V, Pignon JP. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. ASCO Annual Meeting. 2007.Google Scholar
  7. 7.
    Iwasaki Y, Sasako M, Yamamoto S, et al. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). J Surg Oncol. 2013;107(7):741–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol. 2007;25(15):2107–16.CrossRefPubMedGoogle Scholar
  9. 9.
    Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer. 2009;12(1):6–22.CrossRefPubMedGoogle Scholar
  10. 10.
    Serrano OK, Love C, Goldman I, et al. The value of FDG-PET in the staging of gastric adenocarcinoma: a single institution retrospective review. J Surg Oncol. 2016;113(6):640–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Li P, Liu Q, Wang C, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer after surgical resection: a systematic review and meta-analysis. Anna Nuclear Med. 2016;30(3):179–87.CrossRefGoogle Scholar
  12. 12.
    Kudou M, Shiozaki A, Fujiwara H, et al. Efficacy of PET-CT in the diagnosis and treatment of recurrence after esophageal cancer Surgery. Anticancer Res. 2016;36(10):5473–80.CrossRefPubMedGoogle Scholar
  13. 13.
    Pak KH, Yun M, Cheong JH, Hyung WJ, Choi SH, Noh SH. Clinical implication of FDG-PET in advanced gastric cancer with signet ring cell histology. J Surg Oncol. 2011;104(6):566–70.CrossRefPubMedGoogle Scholar
  14. 14.
    Shimada H, Okazumi S, Koyama M, Murakami K. Japanese Gastric Cancer Association Task Force for Research Promotion: clinical utility of 18F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature. Gastric Cancer. 2011;14(1):13–21.CrossRefPubMedGoogle Scholar
  15. 15.
    Yang DM, Kim HC, Jin W, et al. 64 multidetector-row computed tomography for preoperative evaluation of gastric cancer: histological correlation. J Comp Assist Tomogr. 2007;31(1):98–103.CrossRefGoogle Scholar
  16. 16.
    Hasegawa S, Yoshikawa T, Shirai J, et al. A prospective validation study to diagnose serosal invasion and nodal metastases of gastric cancer by multidetector-row CT. Ann Surg Oncol. 2013;20(6):2016–22.CrossRefPubMedGoogle Scholar
  17. 17.
    Japanese Gastric Cancer A. Japanese classification of gastric carcinoma: 3rd English edn. Gastric Cancer. 2011;14(2):101–12.Google Scholar
  18. 18.
    Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14(2):113–23.CrossRefGoogle Scholar
  19. 19.
    Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19.CrossRefGoogle Scholar
  20. 20.
    Kim HW, Won KS, Song BI, Kang YN. Correlation of primary tumor FDG uptake with histopathologic features of advanced gastric cancer. Nucl Med Mol Imaging. 2015;49(2):135–42.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Kaneko Y, Murray WK, Link E, Hicks RJ, Duong C. Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancer. J Nucl Med. 2015;56(4):523–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Fukagawa T, Katai H, Mizusawa J, et al. A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). Gastric Cancer. 2018;21(1):68–73.CrossRefPubMedGoogle Scholar
  23. 23.
    Mocellin S, Pasquali S. Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer. The Cochrane database of systematic reviews. 2015(2):Cd009944.Google Scholar
  24. 24.
    Grabinska K, Pelak M, Wydmanski J, Tukiendorf A, d’Amico A. Prognostic value and clinical correlations of 18-fluorodeoxyglucose metabolism quantifiers in gastric cancer. World J Gastroenterol. 2015;21(19):5901–9.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Park JC, Lee JH, Cheoi K, et al. Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor. Eur J Nucl Med Mol Imaging. 2012;39(7):1107–16.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Michihiro Kudou
    • 1
  • Toshiyuki Kosuga
    • 1
  • Takeshi Kubota
    • 1
  • Kazuma Okamoto
    • 1
  • Shuhei Komatsu
    • 1
    • 2
  • Katsutoshi Shoda
    • 1
  • Hirotaka Konishi
    • 1
  • Atsushi Shiozaki
    • 1
  • Hitoshi Fujiwara
    • 1
  • Tomohiro Arita
    • 1
  • Ryo Morimura
    • 1
  • Yasutoshi Murayama
    • 1
  • Yoshiaki Kuriu
    • 1
  • Hisashi Ikoma
    • 1
  • Masayoshi Nakanishi
    • 1
  • Eigo Otsuji
    • 1
  1. 1.Division of Digestive Surgery, Department of SurgeryKyoto Prefectural University of MedicineKyotoJapan
  2. 2.Department of Gastroenterological SurgeryJapanese Red Cross Kyoto Daiichi HospitalKyotoJapan

Personalised recommendations